Filtered By:
Condition: Heart Attack
Countries: Norway Health

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 39 results found since Jan 2013.

Assessment of mental health trajectories before and after myocardial infarction, atrial fibrillation or stroke: analysis of a cohort study in Tromso, Norway (Tromso Study, 1994-2016)
Conclusion The study indicates that mental health problems among individuals with myocardial infarction, atrial fibrillation and stroke may have started to develop several years before the cardiovascular event and suggests that successful CVD rehabilitation may need to consider previous life factors. Future research is recommended to examine whether health promotion measures in a general population also create mental health resilience after a CVD event.
Source: BMJ Open - April 1, 2022 Category: General Medicine Authors: Lorem, G. F., Opdal, I. M., Wilsgaard, T., Schirmer, H., Lochen, M.-L., Olsen, I. P., Steigen, T., Rognmo, K. Tags: Open access, Mental health Source Type: research

Prevalence of atherosclerosis and association with 5-year outcome: The Norwegian Stroke in the Young Study
CONCLUSION: Atherosclerosis is highly prevalent even in young stroke patients. Some areas and increasing NAA are associated with CVEs and death.PMID:35342817 | PMC:PMC8948509 | DOI:10.1177/23969873211059472
Source: Atherosclerosis - March 28, 2022 Category: Cardiology Authors: Beenish Nawaz Annette Fromm Halvor Øygarden Geir E Eide Sahrai Saeed Rudy Meijer Michiel L Bots Kristin M Sand Lars Thomassen Halvor N æss Ulrike Waje-Andreassen Source Type: research

Ethnic inequalities in acute myocardial infarction and stroke rates in Norway 1994–2009: a nationwide cohort study (CVDNOR)
Conclusions: Preventive measures should be aimed at reducing the excess numbers of CVD among immigrants from South Asia and Former Yugoslavia.
Source: BMC Public Health - October 20, 2015 Category: Consumer Health News Authors: Kjersti RabanalRandi SelmerJannicke IglandGrethe TellHaakon Meyer Source Type: research

Validity of self-reported myocardial infarction and stroke in regions with Sami and Norwegian populations: the SAMINOR 1 Survey and the CVDNOR project
Conclusions The sensitivity and PPV of SMI were high and moderate, respectively; for SRS, both of these measures were moderate. Our results show that SMI from the SAMINOR 1 Survey may be used in aetiological/analytical studies in this population due to a high IHD-specific PPV. The SAMINOR 1 questionnaire may also be used to estimate the prevalence of acute myocardial infarction and acute stroke.
Source: BMJ Open - November 29, 2016 Category: Journals (General) Authors: Eliassen, B.-M., Melhus, M., Tell, G. S., Borch, K. B., Braaten, T., Broderstad, A. R., Graff-Iversen, S. Tags: Open access, Epidemiology, Research methods Source Type: research

Distribution of risk factors for cardiovascular disease and the estimated 10-year risk of acute myocardial infarction or cerebral stroke in Sami and non-Sami populations: The SAMINOR 2 Clinical Survey.
CONCLUSIONS: There were no differences in 10-year risk of AMI or CS between the Sami and non-Sami populations in 10 selected municipalities in Northern Norway. PMID: 29806547 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Public Health - May 1, 2018 Category: International Medicine & Public Health Authors: Siri SRA, Braaten T, Jacobsen BK, Melhus M, Eliassen BM Tags: Scand J Public Health Source Type: research

High ward occupancy, bedspacing, and 60  day mortality for patients with myocardial infarction, stroke, and heart failure
ConclusionsPatients with heart failure had higher risk of admission to alternate wards when home ward occupancy was high. These patients may be negatively affected by full wards.
Source: ESC Heart Failure - March 29, 2022 Category: Cardiology Authors: Andreas Asheim, Sara Marie Nilsen, Stina Aam, Kjartan Sarheim Anthun, Fredrik Carlsen, Imre Janszky, Lars Johan Vatten, Johan H åkon Bjørngaard Tags: Original Article Source Type: research

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Publication date: Available online 3 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson, Johan Bodegård, Anna Norhammar Background In patients with type 2 diabetes and a high cardiovascular risk profile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower cardiovascular morbidity and mortality. Using real-world data from clinical practice, we aimed to compare cardiovas...
Source: The Lancet Diabetes and Endocrinology - August 4, 2017 Category: Endocrinology Source Type: research

Dapagliflozin Compared to DPP ‐4 inhibitors is Associated with Lower Risk of Cardiovascular Events and All‐cause Mortality in Type 2 Diabetes Patients (CVD‐REAL Nordic): a multinational observational study
ConclusionsDapagliflozin was associated with lower risks of cardiovascular events and all‐cause mortality compared to DPP‐4i in a in a real‐world clinical setting and broad T2D population.
Source: Diabetes, Obesity and Metabolism - August 1, 2017 Category: Endocrinology Authors: F Persson, T Nystr öm, M E Jørgensen, B Carstensen, H L Gulseth, M Thuresson, P Fenici, D Nathanson, J W Eriksson, A Norhammar, J Bodegard, K I Birkeland Tags: ORIGINAL ARTICLE Source Type: research

Dapagliflozin is associated with lower risk of cardiovascular events and all ‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study
ConclusionsDapagliflozin was associated with lower risks of CV events and all‐cause mortality compared with DPP‐4 inhibitors in a real‐world clinical setting and a broad T2D population.
Source: Diabetes, Obesity and Metabolism - September 8, 2017 Category: Endocrinology Authors: Frederik Persson, Thomas Nystr öm, Marit E. Jørgensen, Bendix Carstensen, Hanne L. Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Jan W. Eriksson, Anna Norhammar, Johan Bodegard, Kåre I. Birkeland Tags: ORIGINAL ARTICLE Source Type: research

Long-Term Exposure to Transportation Noise in Relation to Development of Obesity —a Cohort Study
Conclusion: Our results link transportation noise exposure to development of obesity and suggest that combined exposure from different sources may be particularly harmful. https://doi.org/10.1289/EHP1910 Received: 17 March 2017 Revised: 5 October 2017 Accepted: 9 October 2017 Published: 20 November 2017 Address correspondence to A. Pyko, Institute of Environmental Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden. Telephone: 46(0) 852487561. Email: Andrei.pyko@ki.se Supplemental Material is available online (https://doi.org/10.1289/EHP1910). The authors declare they have no actual or potential competing fina...
Source: EHP Research - November 20, 2017 Category: Environmental Health Authors: Daniil Lyalko Tags: Research Source Type: research

Does a history of cardiovascular disease or cancer affect mortality after SARS-CoV-2 infection?
Abstract BACKGROUND: Cardiovascular disease and cancer have been described as possible risk factors for COVID-19 mortality. The purpose of this study was to investigate whether a history of cardiovascular disease or cancer affects the risk of dying after a COVID-19 diagnosis in Norway. MATERIAL AND METHOD: Data were compiled from the Norwegian Surveillance System for Communicable Diseases, the Norwegian Cardiovascular Disease Registry and the Cancer Registry of Norway. Univariable and multivariable regression models were used to calculate both relative and absolute risk. RESULTS: In the first half of 20...
Source: Tidsskrift for den Norske Laegeforening - February 2, 2021 Category: General Medicine Authors: Kvåle R, Bønaa KH, Forster R, Gravningen K, Júlíusson PB, Myklebust TÅ Tags: Tidsskr Nor Laegeforen Source Type: research

Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Diabetes Metab. 2023 Jan 3:101418. doi: 10.1016/j.diabet.2022.101418. Online ahead of print.ABSTRACTBACKGROUND: Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to similar therapies.METHODS: The EMPRISE Europe and Asia study is a non-interventional cohort study using data from 2014-2019 in seven European (Denmark, Finland, Germany, Norway, Spain, Sweden, United Kingdom) and four Asian (Israel, Japan, South Korea, Taiwan) countries. Patients with type 2 d...
Source: Diabetes and Metabolism - January 7, 2023 Category: Endocrinology Authors: Avraham Karasik Stefanie Lanzinger Elise Chia-Hui Tan Daisuke Yabe Dae Jung Kim Wayne H-H Sheu Cheli Melzer-Cohen Reinhard W Holl Kyoung Hwa Ha Kamlesh Khunti Francesco Zaccardi Anuradhaa Subramanian Krishnarajah Nirantharakumar Thomas Nystr öm Leo Niska Source Type: research